Yüklüyor......
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement‐dependent anti‐tumor activity of trastuzumab and pertuzumab
The therapeutic potential of anticancer antibodies is limited by the resistance of tumor cells to complement‐mediated attack, primarily through the over‐expression of membrane complement regulatory proteins (mCRPs: CD46, CD55 and CD59). Trastuzumab, an anti‐ HER2 monoclonal antibody, approved for th...
Kaydedildi:
| Yayımlandı: | Mol Oncol |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528480/ https://ncbi.nlm.nih.gov/pubmed/23474221 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.02.011 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|